Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma-Reference-Cited by-同舟云学术

Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma

Published:2010-11 Issue:9 Volume:33 Page:983-990
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Louis Chrystal U.,Straathof Karin,Bollard Catherine M.,Ennamuri Sravya,Gerken Claudia,Lopez Teresita T.,Huls M. Helen,Sheehan Andrea,Wu Meng-Fen,Liu Hao,Gee Adrian,Brenner Malcolm K.,Rooney Cliona M.,Heslop Helen E.,Gottschalk Stephen

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference40 articles.

1. Nasopharyngeal carcinoma;Chan;Ann Oncol,2002

2. Epstein-Barr Virus in the pathogenesis of NPC;Raab-Traub;Semin Cancer Biol,2002

3. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century;Mould;Br J Radiol,2002

4. Childhood nasopharyngeal carcinoma: from biology to treatment;Ayan;Lancet Oncol,2003

5. Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome;Lee;Radiat Oncol,2010

Cited by 205 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized Phase 3 trial;Annals of Oncology;2024-09

2. Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review;Pathogens;2024-08-28

3. Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses;Blood Advances;2024-07-12

4. Characterization of unique pattern of immune cell profile in patients with nasopharyngeal carcinoma through flow cytometry and machine learning;Journal of Cellular and Molecular Medicine;2024-06

5. Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma;npj Precision Oncology;2024-05-16